Michael Staehler

22.4k total citations · 4 hit papers
266 papers, 11.6k citations indexed

About

Michael Staehler is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Cancer Research. According to data from OpenAlex, Michael Staehler has authored 266 papers receiving a total of 11.6k indexed citations (citations by other indexed papers that have themselves been cited), including 215 papers in Pulmonary and Respiratory Medicine, 102 papers in Molecular Biology and 75 papers in Cancer Research. Recurrent topics in Michael Staehler's work include Renal cell carcinoma treatment (196 papers), Renal and related cancers (95 papers) and Cancer Genomics and Diagnostics (71 papers). Michael Staehler is often cited by papers focused on Renal cell carcinoma treatment (196 papers), Renal and related cancers (95 papers) and Cancer Genomics and Diagnostics (71 papers). Michael Staehler collaborates with scholars based in Germany, United States and France. Michael Staehler's co-authors include Axel Bex, Börje Ljungberg, Saeed Dabestani, Thomas Lam, Lorenzo Marconi, Fabian Hofmann, Alessandro Volpe, Karim Bensalah, Markus A. Kuczyk and Thomas Powles and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Michael Staehler

253 papers receiving 11.4k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

EAU Guidelines on Renal Cell Carcinoma: 2014 Update

2015 2.1k citations Börje Ljungberg, Karim Bensalah et al. European Urology profile →
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update

2019 1000 citations Börje Ljungberg, Laurence Albigès et al. European Urology profile →
Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

2009 864 citations Bernard Escudier, Tim Eisen et al. Journal of Clinical Oncology profile →
Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy

2015 380 citations Lorenzo Marconi, Saeed Dabestani et al. European Urology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Michael Staehler	8.6k	5.6k	2.6k	2.3k	2.2k	266	11.6k
Alessandro Volpe	8.0k 0.9×	5.4k 1.0×	1.6k 0.6×	1.4k 0.6×	2.4k 1.1×	140	9.4k
Axel Bex	10.9k 1.3×	7.5k 1.3×	3.4k 1.3×	3.6k 1.5×	3.9k 1.7×	341	14.8k
Mohamad E. Allaf	8.7k 1.0×	4.7k 0.8×	1.1k 0.4×	1.3k 0.6×	3.6k 1.6×	366	11.1k
Thomas Lam	7.7k 0.9×	4.0k 0.7×	1.6k 0.6×	1.6k 0.7×	2.5k 1.1×	90	10.1k
R. Houston Thompson	12.6k 1.5×	7.6k 1.4×	2.3k 0.9×	4.8k 2.1×	5.5k 2.5×	424	18.5k
Umberto Capitanio	9.7k 1.1×	4.3k 0.8×	1.6k 0.6×	1.9k 0.8×	4.2k 1.9×	416	12.7k
Jonathan Coleman	5.5k 0.6×	2.5k 0.5×	1.2k 0.4×	1.1k 0.4×	2.9k 1.3×	300	8.7k
Igor Frank	8.4k 1.0×	4.7k 0.8×	1.5k 0.6×	2.8k 1.2×	5.7k 2.6×	243	13.2k
Stephen A. Boorjian	12.2k 1.4×	6.4k 1.2×	2.2k 0.8×	3.9k 1.7×	9.3k 4.2×	569	20.8k
Surena F. Matin	8.0k 0.9×	5.1k 0.9×	1.8k 0.7×	1.9k 0.8×	6.6k 3.0×	392	13.1k

Countries citing papers authored by Michael Staehler

Since Specialization

Citations

This map shows the geographic impact of Michael Staehler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Staehler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Staehler more than expected).

Fields of papers citing papers by Michael Staehler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Staehler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Staehler. The network helps show where Michael Staehler may publish in the future.

Co-authorship network of co-authors of Michael Staehler

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Staehler. A scholar is included among the top collaborators of Michael Staehler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Staehler. Michael Staehler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vaishampayan, Ulka N., et al.. (2025). Patient Perspective on Medical Conditions Post Immune Checkpoint Therapy in Advanced Renal Carcinoma. 12(2). 1–9.

Holzgreve, Adrien, Marcus Unterrainer, Hans Peter Schmid, et al.. (2025). Changes of Prostate-Specific Membrane Antigen-Radioligand Uptake on PET with Systemic Therapy in Patients with Metastatic Renal Cell Carcinoma. Cancers. 17(11). 1736–1736.

Battle, Dena, et al.. (2024). Real world data on treatment of chromophobe renal cell carcinoma.. Journal of Clinical Oncology. 42(4_suppl). 409–409. 1 indexed citations

Staehler, Michael, Umberto Basso, Jean‐Christophe Eymard, et al.. (2024). A Prospective Non-interventional Real-World Study of cabozantinib in Pretreated Patients With Advanced Renal Cell Carcinoma Refractory to Vascular Endothelial Growth Factor-Targeted Therapy (CASSIOPE). Clinical Genitourinary Cancer. 23(1). 102285–102285.

Staehler, Michael, et al.. (2023). Long-Term Follow-Up in Patients Undergoing Renal Mass Biopsy: Seeding is not Anecdotal. Clinical Genitourinary Cancer. 22(2). 189–192. 4 indexed citations

Staehler, Michael, et al.. (2023). Financial toxicity in patients with metastatic renal cell carcinoma on combination therapy.. Journal of Clinical Oncology. 41(6_suppl). 651–651. 2 indexed citations

Volz, Yannic, Lennert Eismann, Friedrich Jokisch, et al.. (2022). The Burden of Fear of Cancer Recurrence in Genitourinary Cancers: A Prospective Study (NCT04535921). Oncology Research and Treatment. 45(12). 744–751. 5 indexed citations

Spek, Annabel, Anno Graser, Jozefina Casuscelli, et al.. (2021). Dynamic contrast-enhanced CT-derived blood flow measurements enable early prediction of long term outcome in metastatic renal cell cancer patients on antiangiogenic treatment. Urologic Oncology Seminars and Original Investigations. 40(1). 13.e1–13.e8. 1 indexed citations

Bergerot, Cristiane Decat, Dena Battle, Errol J. Philip, et al.. (2020). Fear of Cancer Recurrence in Patients With Localized Renal Cell Carcinoma. JCO Oncology Practice. 16(11). e1264–e1271. 17 indexed citations

10.

Correa, Rohann, Alexander V. Louie, Nicholas G. Zaorsky, et al.. (2019). Reply to Francesco Montorsi, Alessandro Larcher, and Umberto Capitanio’s Letter to the Editor re: Rohann J.M. Correa, Alexander V. Louie, Nicholas G. Zaorsky, et al. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Eur Urol Focus. 2019 Jun 24. pii: S2405-4569(19)30157-9. https://doi.org/10.1016/j.euf.2019.06.002. [Epub ahead of print]. European Urology Focus. 7(2). 404–405. 1 indexed citations

11.

Marcon, Julian, Anno Graser, David Horst, et al.. (2019). Papillary vs clear cell renal cell carcinoma. Differentiation and grading by iodine concentration using DECT—correlation with microvascular density. European Radiology. 30(1). 1–10. 69 indexed citations

12.

George, Daniel J., Jean-François Martini, Michael Staehler, et al.. (2018). Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis. Clinical Cancer Research. 25(4). 1165–1173. 18 indexed citations

13.

Rini, Brian I., Bernard Escudier, Jean-François Martini, et al.. (2018). Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib. Clinical Cancer Research. 24(18). 4407–4415. 45 indexed citations

14.

Dabestani, Saeed, Christian Beisland, Grant D. Stewart, et al.. (2018). Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis. European Urology Focus. 5(5). 857–866. 65 indexed citations

15.

Bex, Axel, Laurence Albigès, Börje Ljungberg, et al.. (2018). Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma. European Urology. 74(6). 805–809. 69 indexed citations

16.

Karl, Alexander, Alexander Büchner, Michael Staehler, et al.. (2013). A New Concept for Early Recovery after Surgery for Patients Undergoing Radical Cystectomy for Bladder Cancer: Results of a Prospective Randomized Study. The Journal of Urology. 191(2). 335–340. 146 indexed citations

17.

Karl, Alexander, M. Seitz, Michael Staehler, et al.. (2011). „Fast track“ bei der radikalen Zystektomie. Der Urologe. 50(9). 1072–1075. 4 indexed citations

18.

Escudier, Bernard, Cezary Szczylik, Thomas E. Hutson, et al.. (2009). Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 27(8). 1280–1289. 378 indexed citations

19.

Escudier, Bernard, Tim Eisen, Walter M. Stadler, et al.. (2009). Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Journal of Clinical Oncology. 27(20). 3312–3318. 864 indexed citations breakdown →

20.

Oberneder, R., M. Kriegmair, Michael Staehler, & A. Hofstetter. (1997). Immuntherapie des metastasierten NierenzellkarzinomsIst der klinische Einsatz in Anbetracht der Ergebnisse, Nebenwirkungen und Kosten gerechtfertigt?. Der Urologe. 36(2). 130–137. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact